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Assessment of laboratory test utilization for HIV/AIDS 
care in urban ART clinics of Lilongwe, Malawi
   Abstract
Background
The 2011 Malawi HIV guidelines promote CD4 monitoring 
for pre-ART assessment and considering HIVRNA 
monitoring for ART response assessment, while some clinics 
used CD4 for both. We assessed clinical ordering practices 
as compared to guidelines, and determined whether the 
samples were successfully and promptly processed. 
Methods
We conducted a retrospective review of  all patients seen in 
from August 2010 through July 2011,, in two urban HIV-care 
clinics that utilized 6-monthly CD4 monitoring regardless 
of  ART status. We calculated the percentage of  patients 
on whom clinicians ordered CD4 or HIVRNA analysis. 
For all samples sent, we determined rates of  successful lab-
processing, and mean time to returned results. 
Results
 Of  20581 patients seen, 8029 (39%) had at least one blood 
draw for CD4 count. Among pre-ART patients, 2668/2844 
(93.8%) had CD4 counts performed for eligibility. Of  all CD4 
samples sent, 8082/9207 (89%) samples were successfully 
processed. Of  those, mean time to processing was 1.6 days 
(s.d 1.5) but mean time to results being available to clinician 
was 9.3 days (s.d. 3.7). Regarding HIVRNA, 172 patients of  
17737 on ART had a blood draw and only 118/213 (55%) 
samples were successfully processed.  Mean processing time 
was 39.5 days (s.d. 21.7); mean time to results being available 
to clinician was 43.1 days (s.d. 25.1).  During the one-year 
evaluated, there were multiple lapses in processing HIVRNA 
samples for up to 2 months. 
Conclusions
Clinicians underutilize CD4 and HIVRNA as monitoring 
tools in HIV care. Laboratory processing failures and 
turnaround times are unacceptably high for viral load 
analysis. Alternative strategies need to be considered in order 
to meet laboratory monitoring needs.  
Introduction
With increasing access to antiretroviral therapy for HIV-
infected individuals in resource-limited settings, the need for 
establishing appropriate treatment monitoring strategies is 
required1.  CD4 count analysis, a long-time determinant of  
antiretroviral therapy (ART) eligibility2, has commonly been 
used for monitoring treatment failure, but immunological 
monitoring is poor at recognizing treatment failure compared 
to virologic monitoring3. 
Specifically in Malawi, with an estimated adult prevalence 
rate of  11%4 and increasing population on ART, providing 
monitoring strategies presents an evolving problem.  CD4 
is used to determine need for ART for individuals in stage 
1 and 2 and require reevaluation every 6 months before 
ART initiation. It has also been used for ART treatment 
monitoring in some centers as an established standard, even 
if  not currently per the national guidelines. Meanwhile, HIV 
RNA for monitoring treatment failure is scheduled to be 
part of  standard care by 20155.
However, limited data exist on how effectively current methods 
have been implemented, in terms of  tests being ordered per 
schedule and results being returned on a clinically relevant 
timeline. As monitoring demands evolve, understanding 
whether appropriate testing was ordered and completed is 
necessary for evaluating effectiveness.  Identifying barriers 
that prevented effective laboratory monitoring in the past 
will allow more successful implementation in the future.  
Given the vital role laboratory tests play in providing quality 
HIV care, we aimed to quantify clinician laboratory ordering 
practices, as well as laboratory turnaround time for CD4 




Lighthouse Trust operates two urban HIV-care clinics 
based in Lilongwe, Malawi. Since 2004, both clinics have 
utilized 6-monthly CD4 monitoring for Pre-ART patients 
to determine ART eligibility and to monitor treatment for 
patients on ART. Lighthouse Clinic (LH) is located on 
the central hospital campus, with a neighboring research 
facility; Martin Preuss Centre (MPC) is located near a district 
hospital in central town. Both hospitals are Ministry of  
Health (MOH) facilities with access to laboratories expected 
to be able to do CD4 cell count and HIV RNA load analysis 
on a daily basis, as needed. Both clinics maintain electronic 
medical records (EMR) of  all patient encounters including 
blood draws and lab results.
For each CD4 and HIVRNA sample ordered in clinic, nurses 
draw the blood in the clinic and the sample is sent to the 
MOH laboratory for processing. The results are delivered 
by hand to the clinic, and entered into the EMR by staff, to 
become available to clinicians. The clinic’s monitoring and 
evaluation team follows up with the laboratory on samples if  
results are not returned. 
Study design, population, and data collection
We conducted a retrospective review from electronic medical 
records (EMR) of  all registered patients seen in these 
two clinics from August 2010 through July 2011, and all 
laboratory orders for CD4 cell count and HIVRNA analysis. 
Permission to the data was granted by the Lighthouse Trust, 
Lilongwe, Malawi.  This study was approved by the Malawi 
Institutional Review Board, the National Health Sciences 
Research Committee (NHSRC) as part of  a program 
evaluation of  Lighthouse Trust. 
Exclusion criteria for patients included age below 18 years 
old, and being transferred into care during the period since 
information about previous laboratory evaluation was 
unknown. We excluded a small number of  samples not 
processed by the Ministry of  Health facility, as such samples 
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were ordered for research protocols by research clinicians, 
rather than regular care monitoring, and processed at a 
different research laboratory facility.
For each patient, we collected visit dates, when and if  they 
were initiated on ART, and dates for when blood draws were 
completed for CD4 cell counts and HIVRNA  analysis, using 
blood-draw as a proxy for ordering. Each sample is associated 
with a unique requisition number and electronically recorded 
date. Dates of  blood draw, processing sample, and entering 
results in the EMR are all recorded in the EMR within 2 
days of  receipt by dedicated staff  in the clinics, along with 
the sample result. For each result returned, we recorded 
the outcome (not returned, passed, failed, and voided), test 
value, date for lab processing, and date of  result returned. 
The MOH laboratory receiving all samples had 3 CD4 count 
analyzers (2 BD FACScount, 1 Beckman Coulter EPICS ) 
and one HIVRNA analyzer (Roche). The number of  days 
machines were processing samples were confirmed by the 
laboratory’s records of  what days quality controls were 
completed per machine. 
Data analysis
Data was compiled from the EMR into a Microsoft Access 
database (2007) and analyzed in Stata (version 11.2). We 
calculated the percentage of  patients on whom clinicians 
ordered CD4 or HIVRNA analysis per the schedule 
indicated by the standard of  care. We determined rates of  
successful lab-processing, and the mean times to processing 
samples and returning results. We also looked for periods of  
time when no CD4 counts or viral loads were successfully 
processed, as a proxy for periods of  time with equipment 
failure or shortage of  reagents.
Results
Ordering
Between the two clinics, 20581 eligible patients were seen, 
of  which 17737 (86.2%) were on ART, and 2844 (13.8%) 
were being followed before ART initiation. Based on the 
frequency of  patient visits, 15924/20581 (76.6%) were seen 
at least once per six-month period during the 12 month study 
period, therefore eligible for two blood draws; the remaining 
4657 patients were only seen within a six-month period, and 
therefore would be due for one blood draw. 
Of  the total patients, 8029/20581 (39.0%) had at least 
one blood draw for CD4 count analysis. Among pre-ART 
patients, 2668/2844 (93.8%) had CD4 counts performed 
for eligibility while among ART patients, only 5361/17737 
(30.2%) received CD4 counts for monitoring. 1006/15924 
(6.3%) had 2 or more blood draws for CD4 count analysis 
as per guidelines.  Of  the 8029 with CD4 analysis ordered, 
4399/9043 (48.6%) patients were from LH; 3630/11538 
(31.5%) were from MPC (p value < 0.0001). 
Regarding HIVRNA ordering, 172/17737 of  patients on 
ART (1.0%) had at least one blood draw for HIVRNA 
analysis; 30 patients had 2 or more blood draws. Of  the 172 
patients with HIVRNA analysis ordered, 155/9043 (1.7%) 
patients were from LH; 17/11538 (0.15%) were from MPC 
(p value < 0.0001).
CD4 analysis
Of  9207 CD4 samples sent to the Ministry of  Health 
laboratories, 8082 (89%) samples were returned as successfully 
processed (Table 1). Of  those, mean time to processing was 
1.6 days (s.d 1.5), whereas the internal laboratory standard 
is 2 days. However, mean time to results being available 
to clinician in the EMR was 9.32 days (s.d. 3.7). For both 
measures of  time to processing and time to results available, 
there was statistical difference between the clinics (p value 
<.01) but no clinical difference (within 0.33 days for both). 
Of  365 expected days of  processing, there were a total of  
251 days when clinic samples were run, including weekend 
days, and 203 days when results were entered in the EMR. 
The laboratory processed samples on a total of  272 days. 
There were no gaps in processing samples longer than 4 days. 
HIVRNA analysis
Of  213 samples sent, only 118 (55%) samples were returned 
as successfully processed (Table 1).  Among these 118 
samples, mean processing time was 39.5 days (s.d. 21.9), with 
a wide range from 1 -132 days. Mean time to results being 
available to clinician was 43.1 days (s.d. 25.1).  There was no 
statistical difference between the two clinics on either mean 
time (p value of  0.47 and 0.35 respectively). During the one-
year evaluated, there were a total of  19 work days when 
the machine processed samples, with no regular interval 
and with 6 occurrences of  breaks longer than 2 weeks in 
HIVRNA analysis. No samples were processed from May 
2011 through July 2011. 
Discussion
Clinicians grossly underutilize CD4 and HIVRNA as 
diagnostic and monitoring tools. While CD4 count 
processing success is acceptable, the current 9 day availability 
to clinicians can be improved.  Also, the 93.8% utilization 
reported for pre-ART monitoring is higher than for ART 
monitoring, as a large portion would be in newly diagnosed 
patients on an initial visit, as opposed to those being followed 
on an interval basis.
However, HIVRNA processing, lab availability, and 
turnaround time require marked improvement for effective 
monitoring. Notably, these are the identified problems in the 
most ideal of  scenarios, where the two clinics have electronic 
medical records, access to laboratory equipment and staff  
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with transport mechanisms in place, and dedicated staff  to 
follow up results (though we acknowledge it is possible that 
some samples were processed in the laboratory appropriately 
and not appropriately recorded by the clinic staff, but this 
number is not quantifiable and assumed to be small)
Uptake of  both CD4 and HIVRNA testing differed 
according to clinic site, with LH ordering more tests than 
MPC.  LH, a centre of  excellence for the central region, 
maintains a more mature ART cohort, has more access to 
specialist physicians, and is closer to the primary lab. This 
may explain some differential in lab ordering, particularly 
with respect to HIVRNA testing. HIVRNA ordering is low at 
times of  equipment failure, likely due to clinician knowledge 
of  equipment status. Similarly, clinicians may not order CD4 
for monitoring when processing capacity is low and decide 
to reserve resources for determining ART eligibility. Overall, 
laboratory ordering at both sites compared to country 
guidelines is suboptimal. Strategies to ensure adherence to 
monitoring guidelines can potentially be incorporated into 
the Electronic Monitoring Record through reminders at 
required lab draw dates.
Regarding rates of  successful processing, the laboratory was 
able to provide a much more reliable service for CD4 than 
for HIVRNA. The two BD FACScount analysers were run 
almost daily, while the EPICS served as a back-up machine 
for when the BD machines needed service or reagents. This 
prevented large gaps in processing. However, the HIVRNA 
analysis was dependent on one analyser, which consistently 
had periods of  machine failure and inability to run samples, 
delaying processing. The number of  samples for CD4 analysis 
was also 100 fold of  the number of  HIVRNA samples, 
suggesting higher demand for consistent service. HIVRNA 
samples were run in batches collected over months, resulting 
in wide standard deviations of  turnaround time. 
Due to successful scale-up of  antiretroviral therapy (ART) 
services over the past decade, almost 250,000 HIV-infected 
people were on ART as of  December of  2010, and this 
number is expected to double by 20156. The rate of  finding 
HIVRNA above 1000 copies/ml in clinics across the 
country at comparable settings is 5.8%, with 7.4% at this 
clinic7, suggesting approximately 1300 of  the 17737 patients 
on ART in this study may be failing therapy, underscoring 
the potential benefit from routine HIV RNA analysis as 
proposed, compared to the 172 that received HIVRNA 
analysis under current conditions. As Malawi prepares to 
adopt scheduled HIVRNA analysis for all patients on ART5, 
a clinic the size of  Lighthouse would be expected to have 
the capacity to perform thousands of  HIVRNA per year. 
Laboratory processing failures and turnaround times are 
unacceptably high to reach that goal and more effective 
maintenance of  equipment is required to process samples 
more than 20 days out of  a calendar year. 
Alternative strategies may offer considerable improvement 
before successfully adopting these tests as standard-of-care. 
For CD4 analysis, point-of-care devices offer a practical 
alternative to providing lab results within a patient-visit, 
among other low-cost options8. When not available, SMS 
result reporting may improve the delay between processing 
and results being available to clinicians. For HIVRNA, 
improved equipment support, so the analyser is available to 
process samples more frequently, is needed. The use of  dried 
blood spots would lengthen the life span of  samples, so to 
adequately preserve them until the analyser is accessible. 
Conclusions
Compared to national and clinic guidelines, clinicians 
underutilize CD4 and HIVRNA as staging and monitoring 
tools, respectively. Laboratory processing failures and 
turnaround times are unacceptably high for viral load 
analysis. Alternative strategies need to be considered in order 
to meet laboratory monitoring needs.  
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